Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05498155
Title Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer (OlympiaN)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors AstraZeneca
Indications

Her2-receptor negative breast cancer

Therapies

Olaparib

Durvalumab + Olaparib

Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP | DEU | BEL | AUT


No variant requirements are available.